CTOs on the Move

William Gallagher Associates

www.wgains.com

 
William Gallagher Associates is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.wgains.com
  • 470 Atlantic Ave
    Boston, MA USA 02210
  • Phone: 617.261.6700

Executives

Name Title Contact Details

Similar Companies

Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Our lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials in solid tumor and hematologic indications. Our pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 dose-escalation trial, and KO-539, a menin-MLL inhibitor, currently in preclinical development.

Beta Bionics

Beta Bionics is proud to be a Massachusetts public benefit corporation.

Elicio

Elicio is committed to transforming the lives of patients and their families by re-engineering the body`s immune response to cancer. By combining expertise in materials science and immunology, Elicio is engineering potent vaccines and immuno-therapies for an array of aggressive cancers. The Elicio Amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, the “brain center” of the immune response, to significantly amplify and enhance the body`s own system of defenses, to defeat cancer and stop its recurrence. This substantially enhanced anti-tumor functionality and long-term protective memory could unlock the full potential of the human immune response to eliminate cancer. Elicio`s lead Amphiphile vaccines targeting pancreatic, colorectal, and head and neck cancer will begin initial patient studies in early 2020. Elicio was founded to expand and apply the ground-breaking Amphiphile technology invented and developed in the labs of Darrell Irvine Ph.D., Professor of Biological Engineering and Materials Sciences and Howard Hughes Investigator, at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. Preclinical studies have demonstrated that Elicio`s Amphiphile vaccines target and concentrate in the lymph nodes resulting in unprecedented tumor-specific immune responses and durable cures of aggressive tumor models in mice.

Spine Team Texas

Spine Team Texas is a Southlake, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioInquire

BioInquire is a Athens, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.